Obesity is known to be associated with metabolic and cardiovascular disorders such as insulin resistance, type 2 diabetes, hypertension, or heart failure, all presenting a chronic low-grade inflammatory component. The activation of the NLRP3 inflammasome pathway appears to be linked to the development of cardio-metabolic diseases.
Tumor necrosis factor-α (TNF-α) is a cytokine involved in the regulation of inflammation in several autoimmune and inflammatory disorders such as rheumatoid arthritis, ulcerative colitis, or psoriasis. Anti-TNF biological treatments in place are effective but there is a need for alternatives with novel pharmacological profiles to overcome their limitations.
Recent studies suggest that neutrophils are not only involved in the innate immune response but also may play extended roles in chronic inflammatory disorders and adaptive immune responses as well.
Natural compounds derived from quinoline and isoquinoline have gained significant attention due to their remarkable biological properties, encompassing antibacterial, anticancer and anti-inflammatory activities. Meanwhile, pyrazoles, a prominent class of heterocyclic compounds, exhibit a wide range of biological and pharmaceutical properties.
During the first talk of the Basic Science Seminar sessions at the 2023 EASL International Liver Congress, focusing on the gut-liver axis, Prof. Maria Rescigno from Humanitas University presented data on the interaction between the gut and the liver and the role of microbiota and intestinal permeability in health and disease.
Empress Therapeutics Inc., a Flagship Pioneering firm, has come out of stealth with $50 million in initial funding, a new chief scientific officer and an ambitious plan to file multiple INDs for novel small-molecule compounds over the next two years.
Could a bioactive peptide secreted in the saliva of ticks offer a useful therapy for people who have experienced intracerebral hemorrhage (ICH)? That’s the question Bioxodes SA has set out to answer, and the company is about to move its first-in-class drug candidate, Ir-CPI, which has dual anti-thrombotic and anti-inflammatory effects, into a phase IIa trial in patients with ICH.
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection.
PARP14 is an ADP-ribosyltransferase that transfers ADP-ribose from NAD+ onto the appropriate protein target. PARP14 selectively binds to STAT6 and promotes expression of IL-4-regulated genes, thus modulating inflammatory signaling pathways. PARP14 is overexpressed in tissues from patients with dermatomyositis, atopic dermatitis, psoriasis and other inflammatory disorder cells compared to normal tissues.